Gland Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 11:30 am

Quick Insight

Gland Pharma Ltd, currently priced at ₹2,084 with a market capitalization of ₹34,329 crore, showcases a robust financial profile characterized by a P/E ratio of 31.5 and a commendable return on equity (ROE) of 11.6%. The company maintains a solid operating profit margin (OPM) of 38% and a return on capital employed (ROCE) of 15.9%, indicating efficient utilization of capital. Notably, its interest coverage ratio (ICR) stands at an impressive 57.38x, reflecting strong earnings relative to debt obligations. With promoter holdings at 51.83% and institutional investors (FIIs and DIIs) collectively holding 39.84%, Gland Pharma appears well-positioned for sustained growth. Given these metrics, investors might view the stock as a potentially strong investment in the pharmaceutical sector, provided they remain vigilant about market conditions and valuations.

Competitors of Gland Pharma Ltd

All Competitor Stocks of Gland Pharma Ltd

Quarterly Result

Last Updated: May 31, 2025, 9:11 am

Below is a detailed analysis of the quarterly data for Gland Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 1,030.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,011.00 Cr. (Dec 2024) to 1,030.00 Cr., marking an increase of 19.00 Cr..
• For Expenses, as of Mar 2025, the value is 636.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 620.00 Cr. (Dec 2024) to 636.00 Cr., marking an increase of 16.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 394.00 Cr.. The value appears strong and on an upward trend. It has increased from 391.00 Cr. (Dec 2024) to 394.00 Cr., marking an increase of 3.00 Cr..
• For OPM %, as of Mar 2025, the value is 38.00%. The value appears to be declining and may need further review. It has decreased from 39.00% (Dec 2024) to 38.00%, marking a decrease of 1.00%.
• For Other Income, as of Mar 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 65.00 Cr. (Dec 2024) to 44.00 Cr., marking a decrease of 21.00 Cr..
• For Interest, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Dec 2024) to 3.00 Cr., marking a decrease of 15.00 Cr..
• For Depreciation, as of Mar 2025, the value is 43.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.00 Cr. (Dec 2024) to 43.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 391.00 Cr.. The value appears to be declining and may need further review. It has decreased from 394.00 Cr. (Dec 2024) to 391.00 Cr., marking a decrease of 3.00 Cr..
• For Tax %, as of Mar 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Dec 2024) to 26.00%, marking an increase of 1.00%.
• For Net Profit, as of Mar 2025, the value is 290.00 Cr.. The value appears to be declining and may need further review. It has decreased from 295.00 Cr. (Dec 2024) to 290.00 Cr., marking a decrease of 5.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 17.60. The value appears to be declining and may need further review. It has decreased from 17.91 (Dec 2024) to 17.60, marking a decrease of 0.31.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 5:29 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 12:06 pm

Below is a detailed analysis of the balance sheet data for Gland Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
• For Reserves, as of Mar 2025, the value is 9,739.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,979.00 Cr. (Mar 2024) to 9,739.00 Cr., marking an increase of 760.00 Cr..
• For Borrowings, as of Mar 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4.00 Cr. (Mar 2024) to 5.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 661.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 542.00 Cr. (Mar 2024) to 661.00 Cr., marking an increase of 119.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 10,422.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,541.00 Cr. (Mar 2024) to 10,422.00 Cr., marking an increase of 881.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,745.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,694.00 Cr. (Mar 2024) to 1,745.00 Cr., marking an increase of 51.00 Cr..
• For CWIP, as of Mar 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2024) to 42.00 Cr., marking a decrease of 78.00 Cr..
• For Investments, as of Mar 2025, the value is 2,790.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,386.00 Cr. (Mar 2024) to 2,790.00 Cr., marking an increase of 404.00 Cr..
• For Other Assets, as of Mar 2025, the value is 5,845.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,342.00 Cr. (Mar 2024) to 5,845.00 Cr., marking an increase of 503.00 Cr..
• For Total Assets, as of Mar 2025, the value is 10,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,541.00 Cr. (Mar 2024) to 10,422.00 Cr., marking an increase of 881.00 Cr..

Notably, the Reserves (9,739.00 Cr.) exceed the Borrowings (5.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Gland Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.44 (Mar 23) to 46.90, marking a decrease of 0.54.
• For Diluted EPS (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.43 (Mar 23) to 46.90, marking a decrease of 0.53.
• For Cash EPS (Rs.), as of Mar 24, the value is 67.82. This value is within the healthy range. It has increased from 56.33 (Mar 23) to 67.82, marking an increase of 11.49.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 529.65. It has increased from 483.23 (Mar 23) to 529.65, marking an increase of 46.42.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 529.65. It has increased from 483.23 (Mar 23) to 529.65, marking an increase of 46.42.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 343.92. It has increased from 220.07 (Mar 23) to 343.92, marking an increase of 123.85.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 91.27. This value is within the healthy range. It has increased from 76.82 (Mar 23) to 91.27, marking an increase of 14.45.
• For PBIT / Share (Rs.), as of Mar 24, the value is 70.35. This value is within the healthy range. It has increased from 67.91 (Mar 23) to 70.35, marking an increase of 2.44.
• For PBT / Share (Rs.), as of Mar 24, the value is 68.76. This value is within the healthy range. It has increased from 64.03 (Mar 23) to 68.76, marking an increase of 4.73.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.42 (Mar 23) to 46.90, marking a decrease of 0.52.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.42 (Mar 23) to 46.90, marking a decrease of 0.52.
• For PBDIT Margin (%), as of Mar 24, the value is 26.53. This value is within the healthy range. It has decreased from 34.90 (Mar 23) to 26.53, marking a decrease of 8.37.
• For PBIT Margin (%), as of Mar 24, the value is 20.45. This value exceeds the healthy maximum of 20. It has decreased from 30.85 (Mar 23) to 20.45, marking a decrease of 10.40.
• For PBT Margin (%), as of Mar 24, the value is 19.99. This value is within the healthy range. It has decreased from 29.09 (Mar 23) to 19.99, marking a decrease of 9.10.
• For Net Profit Margin (%), as of Mar 24, the value is 13.63. This value exceeds the healthy maximum of 10. It has decreased from 21.54 (Mar 23) to 13.63, marking a decrease of 7.91.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 13.63. This value is within the healthy range. It has decreased from 21.54 (Mar 23) to 13.63, marking a decrease of 7.91.
• For Return on Networth / Equity (%), as of Mar 24, the value is 8.85. This value is below the healthy minimum of 15. It has decreased from 9.81 (Mar 23) to 8.85, marking a decrease of 0.96.
• For Return on Capital Employeed (%), as of Mar 24, the value is 12.50. This value is within the healthy range. It has decreased from 13.89 (Mar 23) to 12.50, marking a decrease of 1.39.
• For Return On Assets (%), as of Mar 24, the value is 7.24. This value is within the healthy range. It has decreased from 8.89 (Mar 23) to 7.24, marking a decrease of 1.65.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 23) to 0.01, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.03, marking an increase of 0.03.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.58. It has increased from 0.43 (Mar 23) to 0.58, marking an increase of 0.15.
• For Current Ratio (X), as of Mar 24, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 9.46 (Mar 23) to 4.04, marking a decrease of 5.42.
• For Quick Ratio (X), as of Mar 24, the value is 2.85. This value exceeds the healthy maximum of 2. It has decreased from 6.80 (Mar 23) to 2.85, marking a decrease of 3.95.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.25. This value is below the healthy minimum of 4. It has increased from 1.10 (Mar 23) to 1.25, marking an increase of 0.15.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 57.38. This value is within the healthy range. It has decreased from 169.90 (Mar 23) to 57.38, marking a decrease of 112.52.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 30.48. This value is within the healthy range. It has decreased from 113.46 (Mar 23) to 30.48, marking a decrease of 82.98.
• For Enterprise Value (Cr.), as of Mar 24, the value is 28,818.28. It has increased from 17,126.99 (Mar 23) to 28,818.28, marking an increase of 11,691.29.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.09. This value exceeds the healthy maximum of 3. It has increased from 4.73 (Mar 23) to 5.09, marking an increase of 0.36.
• For EV / EBITDA (X), as of Mar 24, the value is 19.17. This value exceeds the healthy maximum of 15. It has increased from 13.54 (Mar 23) to 19.17, marking an increase of 5.63.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.36. This value exceeds the healthy maximum of 3. It has decreased from 5.76 (Mar 23) to 5.36, marking a decrease of 0.40.
• For Price / BV (X), as of Mar 24, the value is 3.48. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 23) to 3.48, marking an increase of 0.85.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.36. This value exceeds the healthy maximum of 3. It has decreased from 5.76 (Mar 23) to 5.36, marking a decrease of 0.40.
• For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness